<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

CU Cancer Center News and Stories


Research    Breast Cancer    DNA   

Researchers Find Less Risky Way to Monitor Breast Cancer Progression

Researchers at the University of Colorado Anschutz Medical Campus have discovered how to extract critical information about breast cancer tumors and disease progression by analyzing blood plasma rather than using more invasive tissue biopsies.

“This is simply a blood draw,” said the study’s senior co-author Peter Kabos, MD, associate professor of medicine in the medical oncology division at the University of Colorado School of Medicine and CU Cancer Center member. “This allows us to look under the surface to see the defining characteristics of the disease. The advantage is that we don’t need to do repeated tissue biopsies.”

Author David Kelly | Publish Date August 25, 2022
Full Story

Cancer    DNA    Irinotecan    AZD0156

Irinotecan breaks cancer cell DNA – AZD0156 keeps the body from repairing it

The chemotherapy drug irinotecan creates DNA damage leading to cell death and is used to treat colorectal cancer, among other cancer types. Now a University of Colorado Cancer Center study presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 suggests a way to make irinotecan work even better: When researchers added the experimental drug AZD0156 to irinotecan, colorectal cancer cells and models of human colorectal cancer tumors grown in mice both showed significantly more cancer cell inhibition than with irinotecan used alone. An ongoing phase 1 clinical trial is currently testing the combination against advanced solid tumors (NCT02588105).

Author Cancer Center | Publish Date April 03, 2019
Full Story

CU Cancer Center In the News

Health Imaging

New Lesion Measurement Assesses Treatment Responses More Accurately than RECIST

news outletHealth Imaging
Publish DateSeptember 30, 2022

A new way of assessing cancer lesions’ response to treatment could pave the way for developing new cancer therapeutics.

Full Story
Targeted Oncology

Clinical Commentary: Managing Adverse Events From PARP Inhibitors in Advanced Ovarian Cancer

news outletTargeted Oncology
Publish DateSeptember 30, 2022

PARP inhibitors can play a significant role in the first-line setting for patients with advanced ovarian cancer.

Full Story

ODAC Votes Against Safety Profile of Secura Bio’s P13K Inhibitor

news outletBiospace
Publish DateSeptember 26, 2022

In an 8-4 vote, the FDA’s Oncologic Drugs Advisory Committee Roster voted against the benefit-risk profile of Secura Bio’s P13K inhibitor Copiktra.

Full Story
Cancer Health

Abortion Ban Will Harm Women Diagnosed with Breast Cancer During Pregnancy

news outletCancer Health
Publish DateSeptember 22, 2022

Two CU Cancer Center members detail how the Supreme Court decision in Dobbs V. Jackson Women’s Health Organization will harm some patients.

Full Story